Is it appropriate to prescribe trazodone for insomnia in a 79-year-old male, and what dosing and safety considerations are recommended?

Do Not Prescribe Trazodone for Insomnia in This 79-Year-Old Male

The 2019 VA/DoD clinical practice guidelines explicitly advise against using trazodone for chronic insomnia disorder, and this recommendation is particularly important for a 79-year-old patient given the significant safety concerns in elderly populations. 1

Why Trazodone Should Be Avoided

Lack of Efficacy Evidence

The systematic review underlying the VA/DoD guidelines found that trazodone (50-150 mg at bedtime) showed no differences compared to placebo in:

• Sleep efficiency
• Sleep onset latency
• Total sleep time
• Wake after sleep onset
• Rate of discontinuation due to adverse events

The only benefit was subjective sleep quality improvement, but this minimal benefit was deemed insufficient given the adverse effect profile 1.

Critical Limitations of the Evidence Base

The studies supporting trazodone had severe methodological flaws:

• Very short treatment durations (mean 1.7 weeks)
• Follow-up of only 1-4 weeks
• Low-quality evidence overall 1

Significant Safety Concerns in Elderly Patients

Falls are the most frequent adverse event, occurring in 30% of elderly patients taking trazodone 2. Additional concerning adverse effects include:

• Orthostatic hypotension (particularly dangerous in a 79-year-old)
• Sedation and daytime drowsiness
• Dizziness and psychomotor impairment
• High discontinuation rates due to side effects 3

The FDA label specifically notes that trazodone should be "used with caution in geriatric patients" 4, and the limited experience in elderly populations raises additional safety concerns.

What to Prescribe Instead

First-Line Pharmacologic Options

For sleep onset insomnia:

• Low-dose doxepin (3-6 mg): FDA-approved, demonstrated efficacy in older adults with improved Insomnia Severity Index scores at 4 weeks, with no significant difference in adverse events compared to placebo 1
• Ramelteon: Appropriate for sleep-onset difficulties 5

For sleep maintenance insomnia:

• Low-dose doxepin (3-6 mg): Preferred option 1, 5
• Suvorexant: Orexin receptor antagonist with evidence for sleep maintenance 5

For both sleep onset and maintenance:

• Eszopiclone or zolpidem extended-release: Nonbenzodiazepine BZRAs that improved sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset 1
  • Critical caveat: Use lowest effective dose for shortest duration
  • Counsel patient on FDA safety warning regarding complex sleep behaviors (sleep-driving, sleepwalking) 1

Important Exclusions

Avoid benzodiazepines in this 79-year-old patient due to:

• Risk of falls and cognitive impairment in older patients
• Dependency and diversion potential
• Respiratory depression risk 1

Clinical Decision Algorithm

1. Screen for underlying causes: Depression, sleep apnea, medication side effects, pain
2. Recommend cognitive behavioral therapy for insomnia (CBT-I) as first-line non-pharmacologic treatment
3. If pharmacotherapy needed, characterize the insomnia pattern:
   • Sleep onset only → Low-dose doxepin (3-6 mg) or ramelteon
   • Sleep maintenance only → Low-dose doxepin (3-6 mg) or suvorexant
   • Both → Eszopiclone or zolpidem ER
4. Start at lowest dose and titrate based on response
5. Plan for short-term use with regular reassessment

Common Pitfalls to Avoid

• Do not prescribe trazodone simply because it's commonly used: Despite being the second most commonly prescribed agent for insomnia 3, widespread use does not equal evidence-based practice
• Do not assume "low-dose" trazodone is safer: Even at 25-100 mg, adverse events remain significant in elderly patients 6
• Do not ignore the 2019 Beers Criteria: These strongly recommend avoiding antihistamines in older adults due to antimuscarinic effects 1
• Do not prescribe without counseling: Any hypnotic requires discussion of risks, particularly complex sleep behaviors with nonbenzodiazepine BZRAs 1

The Bottom Line

Decline the trazodone request and offer evidence-based alternatives. The most recent high-quality guideline evidence (2020 VA/DoD guidelines) explicitly recommends against trazodone for chronic insomnia, particularly given this patient's age and fall risk. Low-dose doxepin (3-6 mg) represents the best-evidenced alternative for this 79-year-old male, with demonstrated efficacy in older adults and a favorable safety profile 1.